amcure GmbH

amcure leverages its exceptional knowledge of CD44 target biology to develop a novel therapeutic approach to treat metastatic squamous tumors. In cancer, blocking the extracellular target CD44v6 has a beneficial impact on several relevant receptor tyrosine kinase pathways. Our first-in-class CD44v6-inhibitor AMC303 entered clinical development in solid tumors in Q4 2016.
Read More

Recent News

  • 2019-03-28 amcure to Present Data on the Mode of Action of its Lead Compound AMC303 at the AACR Annual Meeting 2019. Please read the press release for more information.
  • 2018-10-22 amcure Presents First Clinical Data for Lead Compound AMC303 at ESMO 2018 Congress. Please read the press release for more information.
  • 2018-08-06 amcure Announces First Patient Dosed with AMC303 in Phase Ib Extension Cohort Based on Positive Safety Results. Please read the press release for more information.
  • 2018-04-17 amcure Presents Pre-Clinical Anti-tumor and Anti-Metastatic Effects of AMC303 at AACR. Please read the press release for more information.
  • 2018-01-15 amcure Appoints Biotech Executive Heinz Schwer to its Board. Please read the press release for more information.
  • 2017-09-11 amcure Presents Phase I/Ib Study Design for Lead Compound AMC303 at ESMO 2017 Congress. Please read the press release for more information.
  • 2017-08-31 amcure Receives Additional €1.75M BMBF Research Grant. Please read the press release for more information.


amcure is sponsored by a grant from the German Ministry of Education and Research
Short description: Development of a novel compound for the treatment of metastasizing cancers
Support code: 031B0052

read more